NEWS DETAIL

Syndax宣佈在《臨床腫瘤學雜誌》上發表了Revuforj®（revumenib）聯合地西他濱/西達扎瑞和維奈托克治療復發/難治性NPM1m、KMT2Ar和NUP98r AML的SAVE數據——GlobeNewswire

Syndax宣佈在《臨床腫瘤學雜誌》上發表了Revuforj®（revumenib）聯合地西他濱/西達唑啶和維奈托克治療復發/難治性NPM1m、KMT2Ar和NUP98r AML的SAVE數據…

醫藥資訊 July 2, 2026

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

文章相關商品

系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。

常見問題

Which products are related to this article?

The system matched these relevant products from the article content: 盧修斯 Revumenib 線上購買.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.